The Supervisory Board of Medios AG has appointed Stefan Bauerreis as a member of the Executive Board and as the Company's new Chief Financial Officer, effective April 15, 2026. He succeeds Falk Neukirch, who will step down at his own request at the end of his regular term of office on April 30, 2026.
This leadership transition is significant for Medios AG as the company positions itself for future growth in the competitive specialty pharmaceutical market. With Bauerreis's appointment, Medios gains an experienced finance expert with many years of international leadership experience in industry and at publicly traded companies. He previously served as Chief Financial Officer of the Stabilus Group and held various senior finance positions within the Schaeffler Group for more than two decades, including as CFO for the Europe region and CFO for Germany.
Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this appointment, stating that Bauerreis combines operational excellence with strategic foresight and has demonstrated throughout his career that he can successfully lead companies through periods of transformation. The Supervisory Board is convinced that he will provide important momentum for the future development of Medios.
Stefan Bauerreis brings extensive expertise in Corporate Accounting, Controlling, Financing, and the transformation and management of international companies. In his new role, he will contribute to further expanding the success of the Medios Group and its position as a leading Specialty Pharma company, both nationally and internationally. Bauerreis expressed his commitment to working in the best interest of shareholders and employees as part of the Executive Board.
The timing of this leadership change coincides with several important events for the Medios Group in the 2026 financial year, including the Metzler Small Cap Days in Frankfurt on April 15, the TP ICAP Midcap Conference in Paris on May 6, and the Annual General Meeting on June 10. These events provide opportunities for the new CFO to outline his vision for the company's financial strategy and growth plans.
As Germany's first listed specialty pharmaceutical company, Medios AG faces increasing competition and regulatory challenges in the European healthcare market. The appointment of an experienced CFO with international credentials signals the company's commitment to strengthening its financial management and strategic positioning. Investors and industry observers will be watching how Bauerreis's expertise in transformation and international management translates to Medios's operations across Germany, the Netherlands, Belgium and Spain.
The company's focus on pioneering individualized medicine represents a growing segment of the pharmaceutical industry, and effective financial leadership will be crucial for navigating the complexities of this specialized market. More information on individualized medicine is available at https://app.medios.group/en/individualizedmedicine. The company's corporate website can be accessed at www.medios.group.
This leadership transition occurs as Medios continues to support key partners in the supply chain with innovative solutions and intelligent services. The financial expertise Bauerreis brings to the Executive Board will be instrumental in guiding the company through its next phase of development, particularly as it works to make the most innovative therapies available through partnerships with pharmacies, specialist practices and pharmaceutical companies.
